Abstract 2116P
Background
Body mass index (BMI) and waist circumference (WC) were used to evaluate nutritional status and obesity.We aimed to examine whether preoperative BMI or WC was associated with mortality after cancer surgery.
Methods
As a population-based cohort study, this study used data extracted from the National Health Insurance Service database of South Korea.We included 87,220 adult patients who underwent major cancer surgery with curative intent between January 1, 2016, and December 31, 2020.
Results
A total of 87,220 patients were included in the final analysis, and 1,374 (1.6%) died within 90 days after cancer surgery. In the multivariable logistic regression model, the BMI <18.5/kg/m2 and >35 kg/m2 groups showed 1.98-fold (odds ratio [OR]: 1.98, 95% confidence interval [CI]: 1.58, 2.49; P<0.001) and 2.62-fold (OR: 2.62, 95% CI: 1.26, 5.45; P<0.001) higher 90-day mortality after cancer surgery than did the BMI 18.5–24.9 kg/m2 group. The 25.0–29.9 kg/m2 (P=0.143) and 30.0–34.9 kg/m2 (P=0.109) BMI groups did not show significant differences compared to the BMI 18.5–24.9 kg/m2 group. Compared with the normal WC group, the high (P=0.052) and very high (P=0.236) WC groups also did not show significant differences in terms of 90-day mortality.
Table: 2116P
Subgroup analyses for 90-day mortality according to cancer surgery type
Surgery | OR (95% CI) | P-value |
Lung cancer | ||
BMI: <18.5 | 1.89 (1.08, 3.29) | 0.025 |
BMI: 25.0–29.9 | 0.82 (0.59, 1.14) | 0.235 |
BMI: 30.0–34.9 | 0.97 (0.37, 2.59) | 0.954 |
BMI: >35.0 | 5.91 (1.19, 29.312) | 0.030 |
Gastric cancer | ||
BMI: <18.5 | 2.47 (1.49, 4.10) | <0.001 |
BMI: 18.5–24.9 | 1 | |
BMI: 25.0–29.9 | 0.99 (0.70, 1.39) | 0.944 |
BMI: 30.0–34.9 | 0.32 (0.09, 1.11) | 0.072 |
BMI: >35.0 | 1.62 (0.20, 13.26) | 0.654 |
Colorectal cancer | ||
BMI: <18.5 | 2.36 (1.53, 3.65) | <0.001 |
BMI: 25.0–29.9 | 0.91 (0.68, 1.24) | 0.556 |
BMI: 30.0–34.9 | 1.01 (0.47, 2.19) | 0.979 |
BMI: >35.0 | 4.67 (1.23, 17.73) | 0.024 |
Liver cancer | ||
BMI: <18.5 | 2.22 (1.11, 4.43) | 0.024 |
BMI: 25.0–29.9 | 0.78 (0.52, 1.17) | 0.227 |
BMI: 30.0–34.9 | 0.62 (0.20, 1.94) | 0.409 |
BMI: >35.0 | 1.09 (0.12, 9.88) | 0.941 |
OR, Odds ratio; CI, confidence interval; BMI, body mass index; WC, waist circumference
Conclusions
Preoperative BMI <18.5 kg/m2 and >35 kg/m2 are associated with an elevated risk of 90-day mortality after major cancer surgery. However, preoperative WC was not significantly associated with 90-day mortality after cancer surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
N/A.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2053P - Dehospitalization through outpatient drug release in clinical pharmacy as a strategic cost-minimization action in a public oncology hospital in the Eastern Amazon: A quantitative analysis
Presenter: Kalysta Borges
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06